Daiichi Sankyo, Japan Government To Unite For Duchenne's MD Drug
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to create a separate company to develop a muscular dystrophy drug using funds from the Japan government, possibly with additional money from an investment fund.
Daiichi Sankyo plans to create a separate company to develop a muscular dystrophy drug using funds from the Japan government, possibly with additional money from an investment fund. The new company is to receive as much as $17.7 million from government-backed Innovation Network to develop a Daiichi Sankyo compound for treating Duchenne's MD. Under the plan, Daiichi Sankyo is to name one of its own employees to serve as president of the new firm to carry out joint research. The new firm also is to take the drug through clinical trials the next four years and then Daiichi Sankyo is to acquire the company and take the product to market. (Click here for more - a subscription may be required
)
"Public-Private Partnership To Tackle Muscular Dystrophy" - Nikkei (Japan) (2/14/2013)